Cite

HARVARD Citation

    Patel, A. et al. (2020). Clinical outcomes of IDH2‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib. British journal of haematology. pp. e48-e51. [Online]. 
  
Back to record